By Sarina Isaacs
Jazz Pharmaceuticals announced Chief Executive Bruce Cozadd is stepping down as CEO.
Cozadd, who co-founded the Ireland-based pharmaceutical company in 2003 and has been CEO since 2009, plans to retire as chief executive at the end of next year, upon the appointment of a successor. He will stay on as board chair, said the company.
Jazz added that it is on track to deliver on its full-year 2024 revenue guidance of between $4 billion and $4.1 billion.
The search for a successor will consider both internal and external candidates, the company said.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
December 16, 2024 16:50 ET (21:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。